Brief: Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization
06/03/2026 13:01
March 6 (Reuters) - Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS CLOSES $20 MILLION FINANCING TO ACCELERATE THE ADVANCE OF STENOPARIB TOWARD FDA APPROVAL AND COMMERCIALIZATION Source text: ID:nGNX8LTGTR Further company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic